COMPOUNDS AND METHODS FOR MODULATING SPLICING

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R 1 ;

L is absent, C 1 -C 6 -alkylene, C 1 -C 6 -heteroalkylene, —O—, —S—, —C(O)—, —N(R 4 )—, —N(R 4 )C(O)- or —C(O)N(R 4 )—, wherein each alkylene and heteroalkylene is optionally substituted with one or more R 5 ;

Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 are each independently C(R 6 ) or N;

X and Y are each independently O, C(R 7a )(R 7b ), or N(R 7c ), wherein X and Y are not both O;

each R 1 is independently hydrogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -heteroalkyl, C 1 -C 6 -haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkylene-aryl, C 2 -C 6 alkenylene-aryl, C 1 -C 6 alkylene-heteroaryl, C 2 -C 6 alkenylene-heteroaryl, halo, cyano, oxo, —OR A , —NR B R C , —NR B C(O)R D , —NO 2 , —C(O)NR B R C , —C(O)R D , —C(O)OR D , —SR E , or —S(O) x R D , wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R 8 ; or

two R 1 groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R 8 ;

each R 4 is independently hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -heteroalkyl, C 1 -C 6 -haloalkyl, cycloalkyl, or heterocyclyl, wherein each alkyl, heteroalkyl, haloalkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R 12 ;

each R 5 is independently C 1 -C 6 -alkyl, C 1 -C 6 -heteroalkyl, C 1 -C 6 -haloalkyl, cycloalkyl, heterocyclyl, halo, cyano, oxo, —OR A , —NR B R C , —C(O)R D , or —C(O)OR D ;

R 6 is hydrogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -heteroalkyl, C 1 -C 6 -haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, —OR A , —NR B R C , —C(O)R D , or —C(O)OR D ;

R 7a , R 7b , and R 7c are each independently hydrogen, C 1 -C 6 -alkyl, or halo; or

R 7a and R 7b , together with the carbon atom to which they are attached, form an oxo group;

each R 8 is independently C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -heteroalkyl, C 1 -C 6 -haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, —OR A , —NR B R C , —NR B C(O)R D , —NO 2 , —C(O)NR B R C , —C(O)R D , —C(O)OR D , —SR E , or —S(O) x R D , wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R 11 ;

each R A is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkylene-cycloalkyl, C 1 -C 6 alkylene-heterocyclyl, C 1 -C 6 alkylene-aryl, C 1 -C 6 alkylene-heteroaryl, —C(O)R D , or —S(O) x R D ;

each of R B and R C is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkylene-cycloalkyl, C 1 -C 6 alkylene-heterocyclyl, C 1 -C 6 alkylene-aryl, C 1 -C 6 alkylene-heteroaryl, or —OR A ; or

R B and R C together with the atom to which they are attached form a 3-7-membered heterocyclyl or heteroaryl ring optionally substituted with one or more R 10 ;

each R D and R E is independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkylene-cycloalkyl, C 1 -C 6 alkylene-heterocyclyl, C 1 -C 6 alkylene-aryl, or C 1 -C 6 alkylene-heteroaryl;

each R 10 is C 1 -C 6 -alkyl, halo, cyano, oxo, or —OR A1 ;

each R 11 is independently C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or —OR A ;

each R 12 is independently deuterium, halo, cyano, —OR A , —NR B R C , —NR B C(O)R D , —C(O)NR B R C , —C(O)R D , —C(O)OR D , or —C(O)R D ;

each R A1 is hydrogen or C 1 -C 6 -alkyl;

each of m and n is independently 1 or 2; and

x is 0, 1, or 2.

2 . The compound of claim 1 , wherein A is a monocyclic or bicyclic heterocyclyl.

3 . The compound of any one of the preceding claims, wherein A is a nitrogen-containing heterocyclyl.

4 . The compound of any one of the preceding claims, wherein A is selected from

wherein R 1 is as described in claim 1 .

5 . The compound of any one of the preceding claims, wherein A is selected from:

6 . The compound of any one of the preceding claims, wherein A is selected from

7 . The compound of any one of the preceding claims, wherein B is selected from

wherein R 1 is as described in claim 1 .

8 . The compound of any one of the preceding claims wherein B is selected from NH

9 . The method of any one of the preceding claims, wherein B is selected from,

10 . The compound of any one of the preceding claims, wherein L is —N(R 4 )—, wherein R 4 is selected from hydrogen, C 1 -C 6 alkyl, and cycloalkyl.

11 . The compound of any one of the preceding claims, wherein L is —N(CH 3 )—.

12 . The compound of any one of the preceding claims, wherein four of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 are independently C(R 6 ) (e.g., CH).

13 . The compound of any one of the preceding claims, wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 are each independently C(R 6 ) (e.g., CH).

14 . The compound of any one of claims 1 - 12 , wherein one of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 is independently C(R 6 ).

15 . The compound of any one of the preceding claims, wherein one of Z 2 and Z 5 is each independently N.

16 . The compound of any one of the preceding claims, wherein Z 2 and Z 5 are each independently N.

17 . The compound of any one of the preceding claims, wherein one of X and Y is C(R 7a )(R 7b ), and the other of X and Y is O.

18 . The compound of any one of the preceding claims, wherein X is O and Y is CH 2 .

19 . The compound of any one of claims 1 - 17 , wherein X is CH 2 and Y is O.

20 . The compound of any one of the preceding claims, wherein n and m are both 1.

21 . The compound of any one of claims 1 - 19 , wherein n is 1 and m is 2.

22 . The compound of any one of claims 1 - 19 , wherein n is 2 and m is 1.

23 . The compound of any one of the preceding claims, wherein

is selected from

24 . The compound of any one of the preceding claims, wherein

is selected from

25 . The compound of any one of the preceding claims, wherein

is selected from

26 . The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-a):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , X, Y, R 2b , m, n, and subvariables thereof are as defined in claim 1 .

27 . The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-b):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, Z 1 , Z 2 , Z 3 , Z 4 , X, Y, R 2a , R 2b , m, n, and subvariables thereof are as defined in claim 1 .

28 . The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-c):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, Z 2 , Z 3 , Z 4 , X, m, and subvariables thereof are as defined in claim 1 .

29 . The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-d):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, Z 2 , Z 3 , Z 4 , Y, m, and subvariables thereof are as defined in claim 1 .

30 . The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-e):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, Z 2 , X, Y, m, n, and subvariables thereof are as defined in claim 1 .

31 . The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-f):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, Z 1 , Z 2 , Z 3 , Z 4 , m, and subvariables thereof are as defined in claim 1 .

32 . The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-g):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, Z 1 , Z 2 , Z 3 , Z 4 , n, and subvariables thereof are as defined in claim 1 .

33 . The compound of any one of the preceding claims, wherein compound of Formula (I) is a compound of Formula (I-h):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, Z 1 , Z 2 , Z 3 , Z 4 , R 7c , m, and subvariables thereof are as defined in claim 1 .

34 . The compound of any one of the preceding claims, wherein the compound is selected from any one of the compounds shown in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

35 . A pharmaceutical composition comprising a compound of any one of claims 1 - 34 and a pharmaceutically acceptable excipient.

36 . The compound of any one of claims 1 - 35 or the pharmaceutical composition of claim 36 , wherein the compound alters a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

37 . The compound of any one of claims 1 - 35 or the pharmaceutical composition of claim 36 , wherein the compound binds to a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

38 . The compound of any one of claims 1 - 35 or the pharmaceutical composition of claim 36 , wherein the compound stabilizes a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

39 . The compound of any one of claims 1 - 35 or the pharmaceutical composition of claim 36 , wherein the compound increases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR.

40 . The compound of any one of claims 1 - 35 or the pharmaceutical composition of claim 36 , wherein the compound decreases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR %.

41 . A method of modulating splicing of a nucleic acid (e.g., DNA, RNA, e.g., a pre-mRNA) comprising contacting the nucleic acid with a compound of Formula (I) as described in any one of claims 1 - 35 .

42 . The method of claim 41 , wherein the compound increases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%0, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR.

43 . The method of claim 41 , wherein the compound decreases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR.

44 . A method of forming a complex comprising a component of a spliceosome (e.g., a major spliceosome component or a minor spliceosome component), a nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA), and a compound of Formula (I), comprising contacting the nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA) with a compound of Formula (I) as described in any one of claims 1 - 35 .

45 . The method of claim 44 , wherein the component of a spliceosome is recruited to the nucleic acid in the presence of the compound of Formula (I).

46 . A method of altering the conformation of a nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA) comprising contacting the nucleic acid with a compound of Formula (I) as described in any one of claims 1 - 35 .

47 . The method of claim 46 , wherein the altering comprises forming a bulge in the nucleic acid.

48 . The method of claim 46 , wherein the altering comprises stabilizing a bulge in the nucleic acid.

49 . The method of claim 46 , wherein the altering comprises reducing a bulge in the nucleic acid.

50 . The method of any one of claims 46 - 49 , wherein the nucleic acid comprises a splice site.

51 . A composition for use in treating a disease or disorder in a subject comprising administering to the subject a compound of Formula (I) according to any one of claims 1 - 35 or the pharmaceutical composition of claim 36 .

52 . The composition for use of claim 51 , wherein the disease or disorder comprises a proliferative disease (e.g., cancer, a benign neoplasm, or angiogenesis).

53 . The composition for use of claim 51 , wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.

54 . The composition for use of claim 51 , wherein the disease or disorder comprises neurological disease or disorder.

55 . The composition for use of claim 51 , wherein the disease or disorder comprises Huntington's disease.